Zhonghua yi xue za zhi最新文献

{"title":"[Function evaluation of urinary, bowel, pelvic floor functions of patients after nerve-sparing radical hysterectomy based on CC-PRO137 scale].","authors":"S Luo, Y Yin, L Qiu, H Wang, Y Liu, X M Sun, B L Wang, D Z Qiao, M X Chen, H Jiang, X Wu","doi":"10.3760/cma.j.cn112137-20250709-01683","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20250709-01683","url":null,"abstract":"<p><p><b>Objective:</b> To investigate urinary, bowel, pelvic floor functions in patients underwent nerve-sparing radical hysterectomy(NSRH) based on CC-PRO137(cervical cancer-patient reported outcome 137 scale,CC-PRO137)scale. <b>Methods:</b> In this retrospective study, we retrospectively enrolled 304 patients with primary cervical cancer who underwent type-C1 radical hysterectomy in the Obstetrics and Gynecology Hospital, Fudan University from Oct, 2018 to Jun, 2021. The CC-PRO137 scale was used to evaluate urinary, bowel, pelvic floor functions at two time points: within 6 months and more than 1 year after surgery. Scores for urinary, bowel, and pelvic-floor functions were compared between the two postoperative intervals. <b>Results:</b> The average age of 304 patients was (47.1±10.6) years<b>.</b>Postoperative urinary, bowel, and pelvic floor functions scores within 6 months were (4.24±0.70), (4.41±0.42), and (4.67±0.46), respectively, while scores at 1 year or more postoperatively were (4.32±0.66), (4.44±0.38), and (4.69±0.45); within 6 months postoperatively, patients aged≤45 years exhibited higher urinary, bowel, and pelvic floor functions scores [(4.32±0.63) vs (4.15±0.77), (4.48±0.34) vs (4.35±0.47), (4.77±0.35) vs (4.59±0.52)] compared to patients aged >45 years (<i>P</i><0.05); at 1 year or more postoperatively, patients aged ≤45 years demonstrated higher urinary and pelvic floor functions scores [(4.42±0.56) vs (4.22±0.74), (4.75±0.37) vs (4.64±0.49)] than patients aged >45 years (<i>P</i><0.05), while no statistically significant difference existed in bowel function scores between groups (<i>P</i>>0.05); within 6 months postoperatively, statistically significant differences were observed in urinary, bowel, and pelvic floor functions scores among FIGO(International Federation of Gynecology and Obstetrics) stage Ⅰ, Ⅱ, and Ⅲ patients (all <i>P</i><0.05), whereas at 1 year or more, FIGO stage Ⅱ and Ⅲ patients showed lower urinary function scores compared to stage Ⅰ patients (both <i>P</i><0.05), FIGO stage II patients had lower pelvic floor function scores (<i>P</i>=0.001), but no significant differences existed in bowel function scores across stages (<i>P</i>>0.05); both within 6 months and at 1 year or more postoperatively, statistically significant differences in urinary function scores were found between patients receiving no adjuvant therapy or postoperative chemotherapy only versus those receiving postoperative concurrent chemoradiotherapy (<i>P</i><0.001); at 1 year or more, significant differences in bowel function scores existed between no adjuvant therapy versus concurrent chemoradiotherapy (<i>P</i>=0.030) and borderline significance between chemotherapy only versus concurrent chemoradiotherapy (<i>P</i>=0.070), while pairwise comparisons of pelvic floor function scores showed no statistical significance (<i>P</i><0.05). <b>Conclusions:</b> Nerve-sparing radical hysterectomy for cervical cancer can markedly reduce the complic","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 36","pages":"3188-3194"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese guidelines for cancer pain management in adults (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20250515-01191","DOIUrl":"10.3760/cma.j.cn112137-20250515-01191","url":null,"abstract":"<p><p>Cancer pain, one of the most prevalent and distressing symptoms in cancer patients, is closely associated with diagnosis, treatment, quality of life, and survival outcomes. Effective cancer pain management necessitates multidisciplinary collaboration and multimodal approaches, implemented through comprehensive and personalized strategies throughout the disease course. To address this imperative, the Cancer Pain Integration Therapy Professional Committee of the China Anti-Cancer Association (CACA) convened domestic experts in cancer pain management. Guided by evidence-based, patient-centered, and system-integrated principles, these experts developed the <i>Chinese</i> <i>guidelines for cancer pain management in adults (2025 edition)</i> from the perspective of integrative medicine. The guidelines provide standardized guidances on pain assessment and diagnostic protocols, pharmacotherapy, minimally invasive analgesic techniques, palliative antitumor therapies, treatment-related pain syndromes, refractory cancer pain syndromes, and related domains. This framework aims to enhance healthcare professionals' overall competency in cancer pain diagnosis, treatment, and comprehensive management.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 36","pages":"3148-3174"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Development and challenges of female reproductive reconstruction in China].","authors":"F An, J L Wang","doi":"10.3760/cma.j.cn112137-20250717-01764","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20250717-01764","url":null,"abstract":"<p><p>Female reproductive plastic and rehabilitation, as an emerging interdisciplinary clinical field, focuses on the correction of structural abnormalities, diagnosis and treatment of functional disorders, and aesthetic enhancement of female reproductive organs caused by congenital and acquired factors. Over the past decade, expert teams in China have made significant progress in establishing a professional system in this field, encompassing top-level disciplinary design, expert team cultivation, and the formulation of industry consensus and group standards. Currently, this specialty in China has developed comprehensive definitions and connotations, formed expert teams, filled gaps in clinical research, and established a series of expert consensus documents. However, the field remains in its nascent stage, facing numerous challenges. Such as suboptimal quality and insufficient quantity of clinical data, inconsistent treatment methods between public and private medical institutions, and inadequate professional knowledge among medical practitioners and the general public. This review elaborates on the development of female reproductive plastic and rehabilitation in China over the past decade, covering the contextual background of its emergence, the establishment process of the Female Reproductive Plastic and Rehabilitation Branch under the Chinese Association of Plastic and Aesthetics, the relevant work conducted by expert teams, the existing challenges, and future prospects, while directly addressing current issues and obstacles.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 36","pages":"3131-3135"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The role of immune cells in the pathogenesis and progression of osteoarthritis warrants attention].","authors":"T Shen, Q Jiang","doi":"10.3760/cma.j.cn112137-20250217-00358","DOIUrl":"10.3760/cma.j.cn112137-20250217-00358","url":null,"abstract":"<p><p>Chronic inflammatory infiltration in osteoarthritis (OA) suggests the pivotal contribution of immune cells to disease pathogenesis. This review examines the contributions of both innate immune cells (neutrophils, macrophages, mast cells, natural killer cells, dendritic cells, eosinophils and basophils) and adaptive immune cells (T lymphocytes and B lymphocytes) in OA pathogenesis. This article focuses on the activation and differentiation mechanisms of these immune cells, elucidating their roles in driving synovial inflammation, cartilage degradation, subchondral bone remodeling and osteophyte formation. Furthermore, we discuss the limitations of current research and propose potential avenues for future investigations.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3043-3048"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics and prognosis of basal ganglia infarction following minor trauma with basal ganglia calcification in children].","authors":"Z M Yu, L B Meng, J W Li, J J Jia, H Xiong, F Fang, W H Zhang, C H Ren, J Zhou, M Liu, X Y Yang, S Zhang, L F Dai, X J Tian, X W Zhuo","doi":"10.3760/cma.j.cn112137-20250109-00081","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20250109-00081","url":null,"abstract":"<p><p>Pediatric patients with arterial ischemic stroke admitted to Beijing Children's Hospital from September 2015 to September 2024 were retrospectively included. According to the COIST classification criteria, 50 cases were attributed to basal ganglia infarction following minor trauma with basal ganglia calcification. The clinical characteristics, including the nature of the trauma, clinical manifestations, imaging findings, and laboratory tests, were analyzed. The modified Rankin Scale (mRS) was used to evaluate the prognosis. Among the 50 cases, 29 were male (58%), and 21 were females (42%), with a median age of 1.2 (0.9, 2.4) years [<i>M</i> (<i>Q</i>₁, <i>Q</i>₃)]; 84% (42/50) were ≤ 3 years at onset. A clear history of minor trauma was documented in 46 cases (92%), most commonly falls from beds/sofas or tripping; 24 cases developed stroke symptoms within 10 min after trauma, and 13 cases developed symptoms within 1-3 hours. The most common symptoms were hemiparesis, facial palsy , and transient seizures, with incidence rates of 96% (48/50), 72% (36/50), and 30% (15/50), respectively. Bilateral infarcts occurred in 5 cases (10%), unilateral in 45 (90%). All patients had punctate or linear basal ganglia calcification on CT, with 86% (43/50) showing bilateral calcifications; MRI showed basal ganglia infarction in all cases, with periventricular or corona radiata involvement in 38%(19/50) and thalamic involvement in 16%(8/50). Elevated aspartate aminotransferase(AST) was observed in 20 patients (40%). At discharge, mRS score showed that 50% (25/50) had a favorable prognosis; after a mean follow-up of (4.6±2.5)years, 97.8%(45/46) had a good prognosis. Basal ganglia infarction following minor trauma with basal ganglia calcification predominantly occurs in children under 3 years old. The onset occurs after minor trauma, typically presenting with hemiplegia, facial paralysis, and seizures. Head CT scans reveal calcifications in the basal ganglia, and infarcts may involve the basal ganglia, periventricular and corona radiata, and thalamus, with a minority showing bilateral infarcts. The long-term prognosis is favorable.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3086-3089"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of risk factors and predictive model construction for Roux-en-Y stasis syndrome after distal gastrectomy for gastric cancer].","authors":"P F Liu, Y Y Wu, J W Qian, T Shen, J Qiu, Z Zhang, G H Shen, J H Lang, J Z Wu","doi":"10.3760/cma.j.cn112137-20250411-00902","DOIUrl":"10.3760/cma.j.cn112137-20250411-00902","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To analyze the risk factors and construct a predictive model for Roux-en-Y stasis syndrome (RSS) after distal gastrectomy for gastric cancer. &lt;b&gt;Methods:&lt;/b&gt; A retrospective analysis was conducted on the clinical data of 351 patients who underwent distal gastrectomy for gastric cancer at Suzhou Ninth People Hospital, Affiliated to Soochow University, from January 2012 to December 2023, including 194 males and 157 females, with the age of (60.8±7.9) years. According to the occurrence of RSS, patients were divided into the RSS group (&lt;i&gt;n&lt;/i&gt;=36) and the non-RSS group (&lt;i&gt;n&lt;/i&gt;=315). Multivariate logistic regression analysis was used to identify risk factors for RSS, and a nomogram prediction model was constructed. The predictive ability, accuracy, and clinical applicability of the model were evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). &lt;b&gt;Results:&lt;/b&gt; Patients in the RSS group had higher age, body mass index, proportion with a history of smoking, proportion with diabetes, proportion receiving neoadjuvant chemotherapy, and proportion with delayed postoperative ambulation (&gt;48 h) compared to those in the non-RSS group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). In contrast, patients in the RSS group exhibited lower albumin levels, proportion of tumors located in the gastric body, proportion undergoing laparoscopic surgery, proportion of linear stapler usage, and proportion undergoing duodenal fixation compared to the non-RSS group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). Multivariate logistic regression analysis showed that increased age (&lt;i&gt;OR&lt;/i&gt;=1.080, 95%&lt;i&gt;CI&lt;/i&gt;: 1.011-1.155), elevated body mass index (&lt;i&gt;OR&lt;/i&gt;=1.227, 95%&lt;i&gt;CI&lt;/i&gt;: 1.033-1.457), and delayed postoperative ambulation time (&gt;48-72 h: &lt;i&gt;OR&lt;/i&gt;=3.042, 95%&lt;i&gt;CI&lt;/i&gt;: 1.058-8.747;&gt;72 h: &lt;i&gt;OR&lt;/i&gt;=4.152, 95%&lt;i&gt;CI&lt;/i&gt;: 1.341-12.852) were risk factors for RSS. In contrast, increased albumin levels (&lt;i&gt;OR&lt;/i&gt;=0.821, 95%&lt;i&gt;CI&lt;/i&gt;: 0.687-0.981), tumors located in the gastric body (&lt;i&gt;OR&lt;/i&gt;=0.237, 95%&lt;i&gt;CI&lt;/i&gt;: 0.072-0.788), laparoscopic surgery (&lt;i&gt;OR&lt;/i&gt;=0.293, 95%&lt;i&gt;CI&lt;/i&gt;: 0.106-0.808), the use of linear staplers (&lt;i&gt;OR&lt;/i&gt;=0.224, 95%&lt;i&gt;CI&lt;/i&gt;: 0.090-0.557), and duodenal fixation (&lt;i&gt;OR&lt;/i&gt;=0.154, 95%&lt;i&gt;CI&lt;/i&gt;: 0.033-0.726) were protective factors for RSS. A nomogram prediction model for RSS after distal gastrectomy was constructed based on these parameters. The model achieved an AUC of 0.883 (95%&lt;i&gt;CI&lt;/i&gt;: 0.840-0.927), with a sensitivity of 97.2% and specificity of 70.5%. The calibration curve showed good agreement between predicted and observed values, and the Hosmer-Lemeshow goodness-of-fit test indicated good model fit (&lt;i&gt;P&lt;/i&gt;=0.425). DCA demonstrated satisfactory clinical net benefit for the model. &lt;b&gt;Conclusions:&lt;/b&gt; Advanced age, elevated body mass index, and delayed postoperative ambulation (&gt;48 h) are risk factors for RSS. Higher albumin level, tumor located in the gastric body, laparoscopic surgery, u","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3079-3085"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of a family with familial hyperaldosteronism type Ⅳ due to a mutation in the CACNA1H gene].","authors":"Z F Zhu, A Z Li, Z L Yan, R L Sa, H T Ju, L Lu","doi":"10.3760/cma.j.cn112137-20250409-00883","DOIUrl":"10.3760/cma.j.cn112137-20250409-00883","url":null,"abstract":"<p><p>This study reports on a family with familial hyperaldosteronism type Ⅳ caused by a mutation in the CACNA1H gene. The proband (male, 39 years) presented to the Inner Mongolia Medical University Affiliated Hospital on March 8, 2024, with a 25-year history of episodic weakness and a 5-year history of elevated blood pressure, complicated with hypertension, hypokalemia, elevated urinary potassium excretion, and increased aldosterone-to-renin concentration ratio (ARR), along with a captopril suppression rate of -23.6%. Imaging revealed left adrenal hyperplasia. Genetic sequencing revealed: a heterozygous mutation c.5324-19G>A was identified in the IVS31/IC30 region of the CACNA1H gene. Family screening revealed that 4 family members-his mother, older brother, younger brother, and nephew-carried the variant. Among them, 3 individuals (excluding the nephew) presented with hypertension and elevated ARR, leading to a confirmed diagnosis of familial hyperaldosteronism type Ⅳ. Among 4 cases, including the proband, 3 cases complicated hypokalemia, 3 showed adrenal hyperplasia, and 2 had early-onset cerebrovascular events. Genetic analysis confirmed this intronic variant causes RNA splicing abnormalities. Compared to previously reported pedigrees with exonic missense mutations, this family demonstrated a significantly higher incidence of cerebrovascular complications (50%). Spironolactone treatment effectively normalized blood pressure and serum potassium levels. These findings highlight the necessity of combining ARR assessment, captopril testing, and CACNA1H genetic analysis for familial hyperaldosteronism diagnosis in patients with early-onset hypertension, hypokalemia, and family history of cerebrovascular disease.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3090-3094"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Partial knee arthroplasty: development, current status and future perspectives].","authors":"Y L Xiong, Y L Wang, C Zeng, G H Lei","doi":"10.3760/cma.j.cn112137-20250213-00330","DOIUrl":"10.3760/cma.j.cn112137-20250213-00330","url":null,"abstract":"<p><p>Severe knee joint diseases, such as advanced knee osteoarthritis, often require total knee arthroplasty (TKA) for treatment. However, knee osteoarthritis typically affects only one or two compartments of the knee joint, and TKA inevitably involves the resection and reconstruction of healthy joint compartments. Partial knee arthroplasty (PKA) was developed as a targeted alternative, and after decades of advancement, it has become increasingly refined, demonstrating unique advantages in treating unicompartmental and/or bicompartmental knee joint diseases. This paper focuses on the development and current status of PKA, including unicondylar knee arthroplasty, patellofemoral arthroplasty, and bicompartmental knee arthroplasty. It summarizes patient selection criteria, clinical outcomes, and proposes future directions for further advancements.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3037-3042"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of Telitacicept combined with low-dose mycophenolate mofetil in the treatment of moderate-to-severe systemic lupus erythematosus].","authors":"C Q Zhang, M Zhang, D M Li, L N Li, M Y Zhang, G L Zhang","doi":"10.3760/cma.j.cn112137-20250125-00215","DOIUrl":"10.3760/cma.j.cn112137-20250125-00215","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy of Telitacicept combined with low-dose mycophenolate mofetil (MMF, 1 g/day) in patients with moderate-to-severe systemic lupus erythematosus (SLE). <b>Methods:</b> In this prospective, open-label, randomized controlled trial, 84 patients with active SLE [Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)≥10] were enrolled at Shanxi Provincial People's Hospital from June 2023 to June 2024. The participants were randomized to 2 groups with block randomization sequence: Telitacicept group (the patients were given subcutaneous Telitacicept 160 mg weekly+MMF 1 g/day+prednisone) and the MMF group (the patients were treated with MMF 2 g/day+prednisone). The primary endpoint was non-inferiority in SLEDAI-2K reduction at week 24 (margin Δ=2.0). The secondary endpoints included British Isles Lupus Assessment Group 2004 (BILAG-2004), Physician's Global Assessment (PGA), complement levels, glucocorticoid-tapering success rate (prednisone≤7.5 mg/d), and adverse events. <b>Results:</b> A total of 84 patients with moderate-to-severe SLE were enrolled, including 75 females (89.29%), with a mean age of (39.39±10.68) years. There were 43 cases in the Telitacicept group and 41 cases in the MMF group. The Telitacicept group demonstrated non-inferior SLEDAI-2K reduction [(14.77±5.28) vs (17.32±5.99) points, 95%<i>CI</i> of between-group difference:-1.92 to 0.43]. Compared to the MMF group, the Telitacicept group showed a significantly higher achievement rate of prednisone reduction to≤7.5 mg/d [83.72% (36/43) vs 63.41% (26/41), <i>P</i>=0.034], a lower incidence of infections [23.26% (10/43) vs 68.29% (28/41), <i>P</i><0.001], and a lower anti-dsDNA level [(64.87±44.11) vs (111.92±34.08) U/ml, <i>P</i>=0.001]. In the lupus nephritis subgroup, the 12-week urinary protein remission rate (<0.5 g/24 h) was 90.48% (19/21) in the Telitacicept group, it was higher than that in the MMF group [73.91% (17/23)](<i>P</i>=0.042). The Telitacicept group showed a greater improvement in complement C3 level [(1.03±0.35) vs (0.89±0.29) g/L, <i>P</i>=0.063]. No intergroup differences in BILAG-2004, PGA, or joint symptoms improvement was found between the two groups (all <i>P</i>>0.05). <b>Conclusion:</b> Telitacicept plus low-dose MMF shows comparable efficacy to high-dose MMF for moderate-to-severe SLE, with superior glucocorticoid sparing and reduced infection risk.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3071-3078"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20250417-00951","DOIUrl":"10.3760/cma.j.cn112137-20250417-00951","url":null,"abstract":"<p><p>In recent years, with the discovery of epidermal growth factor receptor (EGFR) gene and the successful development of tyrosine kinase inhibitors (TKI), the treatment efficacy for non-small cell lung cancer (NSCLC) patients with EGFR gene sensitive mutation has been greatly improved. With the increasing variety of EGFR-TKI approved for marketing subsequently, it brings confusion to clinicians when choosing specific medications, and there is an urgent need to develop relevant treatment guidelines. Hence, based on the \"China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)\", the Medical Oncology Branch of China International Exchange Promotive Association for Medical and Health Care and the Chinese Association for Clinical Oncologists organized experts to integrate the research results of various EGFR-TKI, and proposed the \" Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)\", the recommendations have been updated and enriched based on the latest clinical evidence to provide reference for better clinical practice.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 35","pages":"3049-3064"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}